{"brief_title": "Study Evaluating rhIL-11 in Active Crohn's Disease", "brief_summary": "The purpose of this study is to assess the activity of multiple doses of oral rhIL-11 in patients with active Crohn's disease (Crohn's Disease Activity Index [CDAI] score from 220-400).", "condition": "Inflammatory Bowel Disease", "intervention_type": "Drug", "intervention_name": "Recombinant Human Interleukin-11 (rhIL-11)", "criteria": "Inclusion Criteria: - Documented, signed and dated informed consent to participate in this trial prior to any study related procedures being performed. - Men and women age 16 years and over. - Diagnosis of Crohn's disease for at least 6 months that has been appropriately documented and confirmed by radiological studies, endoscopy (with histological examination preferred), or surgical pathology (Patients with a diagnosis of Crohn's disease for less than 6 months may be included if the diagnosis is confirmed by a biopsy characteristic of Crohn's disease) Exclusion Criteria: Use of the following medications within the specified time period prior to randomization: - Nonsteroidal anti-inflammatory drugs (NSAIDs; including Cyclooxygenase-2 [COX-2] inhibitors and >500 mg/day acetylsalicylic acid) - Codeine-containing compounds - Corticosteroid enemas", "gender": "All", "minimum_age": "16 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00040521.xml"}